Vertex Pharmaceuticals Inc. is a global biotechnology company that develops transformative and life-altering medicines for people with significant diseases such as cystic fibrosis. Incorporated in Massachusetts, it is internationally recognized for its continuous dedication to scientific research and innovation.
Established in 1989, the company pivots on transformative drug discovery anchored on serious and life-threatening diseases that have limited treatment options. Trading on the NASDAQ under the symbol 'VRTX', the company has operated successfully for more than three decades.
One of Vertex’s most prominent accomplishments is their pioneering work in cystic fibrosis. Cystic fibrosis is a chronic disease that affects over 70,000 people worldwide. Historically, there have been limited effective treatments for this debilitating condition. However, Vertex has revolutionized the treatment landscape by developing several first-in-class medicines that treat the underlying cause of the condition, thus providing patients with a better quality and potentially longer life.
Besides cystic fibrosis, Vertex is focused on research and development in other specialist disease areas, including sickle cell disease, beta-thalassemia, and AATD (Alpha-1 Antitrypsin Deficiency). Innovations in these areas indicate Vertex's aim to address conditions where patient necessity is high, and medical need is unmet.
Vertex as an entity is deeply committed to corporate responsibility, demonstrating a strong commitment to ethical business practices, improved patient access to their therapies, and sustained investments in their community. It continually seeks to reduce the environmental impact of its operations.
Over the years, the company has built a robust global presence. Vertex employs over 3,000 people in various fields, including research, development, manufacturing, commercial, and corporate roles across its locations in North America, Europe, and Australia.
Financially, Vertex has demonstrated significant strength, reporting net income of $2.7 billion in 2020. This success can be primarily attributed to the commercial success of its cystic fibrosis portfolio and the successful advancement of its pipeline.
In summary, Vertex Pharmaceuticals Inc. remains dynamic in its innovative focus, championing treatment options even for diseases that do have limited existing treatment options. With a patient-centered strategy, Vertex is making strides to ensure that transformative medicines reach those who need them the most.